The anti-inflammatory effect of exogenous lactoferrin on breeding-induced endometritis when administered post-breeding in susceptible mares.
- Journal Article
Summary
The research explores the anti-inflammatory capabilities of lactoferrin, specifically when used post-insemination in horses. The study uncovered that this protein, when administered intrauterinely after breeding, can modify the immune response and appears to be most effective at a 50 μg/mL concentration.
Study Objectives and Methodology
The research had three primary goals:
- Assess the safety of intra-uterine infusion of human recombinant lactoferrin (hrLF),
- Measure the effect of hrLF when administered post-breeding as a potential modulator of the immune response in mares susceptible to persistent breeding-induced endometritis (PBIE), a condition characterized by prolonged inflammation,
- Determine the most effective concentration of hrLF.
Two experiments were conducted as part of this study:
- The first experiment administered 500 μg/mL of hrLF via intrauterine infusion to four normal mares.
- In contrast, the second experiment incorporated six mares susceptible to PBIE. They were bred during estrus with sperm from two stallions, after which four different treatments of hrLF were applied over a series of four estrous cycles.
Post-treatments, mares were evaluated through ultrasonography for fluid retention and endometrial biopsy for identifying inflammatory cytokines.
Results and Conclusion
Results showed that lactoferrin did not have a significant overall impact on vital signs or the quality of the endometrium in mares. However, it did reduce the ratio of polymorphonuclear neutrophils (PMNs) to epithelial cells at all concentrations compared to the untreated horses.
Interestingly, all tested concentrations of hrLF increased the mRNA expression of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RN), indicating a dampening of the inflammatory response.
Particularly, the 50 μg/mL dose of hrLF dramatically suppressed the mRNA expression of the pro-inflammatory cytokine interferon gamma, suggesting an even more pronounced reduction in inflammation at this concentration.
In conclusion, administering hrLF post-breeding shows promising potential in moderating the inflammatory response in horses. The most effective hrLF concentration seemed to be at 50 μg/mL. However, detailed large-scale studies are needed to confirm these findings and further explore this avenue for effective treatment of PBIE in mares.
Cite This Article
Publication
Researcher Affiliations
- Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, 40546-0099, USA. Electronic address: carleigh.fedorka@uky.edu.
- Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, 40546-0099, USA.
- Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, 40546-0099, USA.
- College of Agriculture and Life Sciences, Department of Animal Science, Cornell University, Ithaca, NY, 14853, USA.
- Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, 40546-0099, USA.
- Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, 40546-0099, USA.
- Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY, 40546-0099, USA.
MeSH Terms
- Animals
- Anti-Inflammatory Agents / administration & dosage
- Anti-Inflammatory Agents / pharmacology
- Body Temperature / drug effects
- Breeding
- Cytokines / genetics
- Cytokines / metabolism
- Endometritis / etiology
- Endometritis / prevention & control
- Endometritis / veterinary
- Female
- Gene Expression Regulation / drug effects
- Heart Rate / drug effects
- Horse Diseases / prevention & control
- Horses
- Humans
- Insemination, Artificial / adverse effects
- Insemination, Artificial / veterinary
- Lactoferrin / administration & dosage
- Lactoferrin / pharmacology
- Recombinant Proteins / administration & dosage
- Recombinant Proteins / pharmacology
- Respiration / drug effects
Citations
This article has been cited 9 times.- Nocera FP, Maurizi L, Masullo A, Nicoletti M, Conte AL, Brunetti F, De Martino L, Zagaglia C, Longhi C. Genotypic and Phenotypic Characterization of Escherichia coli Isolates Recovered from the Uterus of Mares with Fertility Problems. Animals (Basel) 2023 May 14;13(10).
- Alghamdi AS, Fedorka CE, Scoggin KE, Esteller-Vico A, Beatty K, Davolli G, Ball BA, Troedsson MHT. Binding of Equine Seminal Lactoferrin/Superoxide Dismutase (SOD-3) Complex Is Biased towards Dead Spermatozoa. Animals (Basel) 2022 Dec 23;13(1).
- Pan Y, Liu Z, Wang Y, Zhang L, Chua N, Dai L, Chen J, Ho CL. Evaluation of the Anti-Inflammatory and Anti-Oxidative Effects of Therapeutic Human Lactoferrin Fragments. Front Bioeng Biotechnol 2021;9:779018.
- Muñoz-Prieto A, Escribano D, Contreras-Aguilar MD, Horvatić A, Guillemin N, Jacobsen S, Cerón JJ, Mrljak V. Tandem Mass Tag (TMT) Proteomic Analysis of Saliva in Horses with Acute Abdominal Disease. Animals (Basel) 2021 Apr 30;11(5).
- Canisso IF, Segabinazzi LGTM, Fedorka CE. Persistent Breeding-Induced Endometritis in Mares - a Multifaceted Challenge: From Clinical Aspects to Immunopathogenesis and Pathobiology. Int J Mol Sci 2020 Feb 20;21(4).
- Nakamura A, Tanaka Y, Takebayashi A, Amano T, Tsuji S. Lactoferrin as a Non-Hormonal Therapeutic Candidate for Endometriosis: Mechanisms and Future Directions. Reprod Sci 2026 Mar 5;.
- Shokrollahi B, Choi JY, Won M, Kim ET, Lee SE, Ham JS. Koumiss (Fermented Mare's Milk) as a Functional Food: Bioactive Proteins, Peptides, and Future Perspectives. Foods 2025 Nov 18;14(22).
- Xin H, Li B, Meng F, Hu B, Wang S, Wang Y, Li J. Quantitative proteomic analysis and verification identify global protein profiling dynamics in pig during the estrous cycle. Front Vet Sci 2023;10:1247561.
- Shen Q, Wu X, Chen J, He C, Wang Z, Zhou B, Zhang H. Immune Regulation of Seminal Plasma on the Endometrial Microenvironment: Physiological and Pathological Conditions. Int J Mol Sci 2023 Sep 27;24(19).